Metrics to compare | ONCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −2.3x | −0.2x | |
PEG Ratio | −0.15 | −0.08 | 0.00 | |
Price/Book | 4.9x | −0.1x | 2.6x | |
Price / LTM Sales | 152.3x | 1.9x | 2.8x | |
Upside (Analyst Target) | - | 171.6% | 60.9% | |
Fair Value Upside | Unlock | −6.4% | 9.5% | Unlock |
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.